Loading
Life sciences · Journal article
Vaccines · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Hand, foot and mouth disease (HFMD) is caused by several enteroviruses, with enterovirus A71 (EV-A71) most strongly associated with severe disease and death. Licensed monovalent inactivated EV-A71 vaccines in China have a substantial evidence base for safety, immunogenicity, protective efficacy, and real-world effectiveness, together with relatively mature clinical evaluation and quality control systems. Their protection, however, is predominantly type-specific and does not extend reliably to major non-EV-A71 enteroviruses such as coxsackievirus A16 (CVA16), CVA6, or CVA10. As EV-A71-associated disease has declined, these viruses have become more prominent among residual cases and outbreaks, although shifts in etiological proportions should not be equated with vaccine-driven type replacement. This review synthesizes evidence on the developmental basis and limits of monovalent EV-A71 vaccination and evaluates multivalent candidates based on inactivated virus, virus-like particles (VLPs), chimeric antigens, and nucleic acid platforms. Most multivalent evidence remains preclinical, and major translational gaps include the absence of population-validated correlates of protection for non-EV-A71 types, uncertain antigenic coverage, component-specific quality control requirements, immune response imbalance, clinical case accrual, pediatric safety, coadministration, and affordability. We therefore propose a stage-gated framework that separates developmental maturity from public health priority and evaluates each additional antigen according to product objectives, sustained absolute disease burden, antigenic coverage, manufacturing readiness, immune response balance, clinical evaluability, and incremental public health value. Under this framework, higher valency is a conditional development choice rather than an objective in itself, and vaccine composition should be adapted to regional epidemiology and measurable added benefit over lower valency comparators.